CD30检测对淋巴瘤诊疗价值的多中心回顾性研究  

Value of CD30 detection in the diagnosis and treatment of lymphoma:a multi-center retrospective study

作　　者：乔泓涵 王亚兰[3] 苏丽萍[4] 白敏[4] 高雪[5] 马荣军[6] 张丹丹[2] 张明智[1] 朱利楠[1] 张旭东[1] QIAO Honghan;WANG Yalan;SU Liping;BAI Min;GAO Xue;MA Rongjun;ZHANG Dandan;ZHANG Mingzhi;ZHU Linan;ZHANG Xudong(First Affiliated Hospital of Zhengzhou University,Lymphoma Diagnosis and Treatment Center of Henan Province,Zhengzhou,Henan450052,China;Department of Hematology,Baotou Tumor Hospital,Baotou,Inner Mongolia 014010,China;Department of Hematology,Shanxi Cancer Hospital,Taiyuan,Shanxi 030013,China;Department of Hematology,Henan Cancer Hospital,Zhengzhou,Henan450008,China;Department of Hematology,Henan Provincial People's Hospital,Zhengzhou,Henan450003,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南省淋巴瘤诊疗中心,河南郑州450052 [2]郑州大学第一附属医院病理科,河南省淋巴瘤诊疗中心,河南郑州450052 [3]包头市肿瘤医院血液科,内蒙古包头014010 [4]山西省肿瘤医院血液科,山西太原030013 [5]河南省肿瘤医院血液科,河南郑州450008 [6]河南省人民医院血液科,河南郑州450003

出　　处：《中华肿瘤防治杂志》2024年第9期569-574,共6页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金(82070210);河南省医学科技攻关重大项目(SBGJ20201008)。

摘　　要：目的分析5所医院CD30病理检测和淋巴瘤临床诊疗情况,以期提高淋巴瘤临床诊断的准确性并有效指导CD30靶向药物在临床中的应用.方法采用回顾性研究,以调查问卷的形式收集2012-04-07-2022-05-27在5所医院(郑州大学第一附属医院、包头市肿瘤医院、山西省肿瘤医院、河南省肿瘤医院和河南省人民医院)诊断为淋巴瘤的142例患者的临床资料.结果对于CD30的表达情况,67例经典霍奇金淋巴瘤和20例间变大细胞淋巴瘤为定性描述;55例其他类型的淋巴瘤病例,5例为定量描述,50例为定性描述.142例患者中,使用维布妥昔单抗23例(16.20%),其中19例为一线治疗,1例为二线治疗,1例为三线治疗,2例为四线治疗;中位用药周期为4个周期(2~6个周期),中位用药时间为3.3个月(0.5~12.0个月).1年无进展生存率和总生存率分别为86.96%和95.65%;应用含维布妥昔单抗一线治疗方案的19例患者中有18例进行了疗效评价,完全缓解8例,部分缓解7例,客观缓解率为83.33%.结论5所医院对CD30免疫组织化学检测的方法及染色结果的判读存在较明显差异,维布妥昔单抗治疗CD30阳性淋巴瘤的疗效较确切,但需要更多真实世界研究数据.Objective To analyze the current situation of CD30pathological detection and clinical diagnosis and treatment among 5hospitals,and to improve the accuracy of clinical diagnosis of lymphoma and effectively guide the application of CD30-directed drugs in clinical practice.Methods This was a multi-center and retrospective study.We collected the clinical data of patients diagnosed with lymphoma from 5real-world Chinese centers from April 7,2012to May 27,2022in the form of a survey.Results Among a total of 142cases,the expression of CD30of 67cases of classical Hodgkin lymphoma and 20cases of anaplastic large-cell lymphoma was qualitatively analyzed,respectively.Additionally,among the remaining 55cases diagnosed with other types of lymphoma,5cases were quantitatively and 50were qualitatively described.The total number of brentuximab vedotin(BV)users among 142patients was 23,and the application rate was 16.20%approximately.Nineteen cases out of 23received BV as the first-line therapy,1as second-line therapy,1as third-line and 2as fourth-line.Patients received a median of 4cycles(range:2-6)of BV treatment,the median medication duration was 3.3months(range:0.5-12.0),and the 1-year PFS and OS rates were 86.96%and 95.65%,respectively.Eighteen out of 19patients underwent effectiveness evaluation,including 8cases of complete response,7cases of partial response,and the objective response rate was 83.33%.Conclusions There are obvious differences in the detection methods and the interpretation results of CD30immunohistochemistry among various centers.Additionally,BV is quite effective in treating CD30-positive lymphoma,but more real-word data is still needed.

关 键 词：CD30 淋巴瘤 免疫组织化学 维布妥昔单抗 真实世界研究 

分 类 号：R733.4[医药卫生—肿瘤]